Funded Biotechnology Startups
The 50 most recent biotechnology funding events cover late October through late November 2025, with disclosed amounts ranging from $230K (ImmunoProfile) to…
The 50 most recent biotechnology funding events cover late October through late November 2025, with disclosed amounts ranging from $230K (ImmunoProfile) to $600M (Kailera Therapeutics, Series B, Waltham, Massachusetts). Six rounds exceeded $100M: Kailera at $600M, Tubulis at $358M Series C out of Munich, Kardigan at $254M Series B in South San Francisco, Hemab at $157M Series C in Copenhagen, and a pair of $115M closes from Artios Pharma (Cambridge, UK, Series D) and Aspen Neuroscience (San Diego, Series C).
US cities lead by volume, with San Diego hosting four companies (Aspen Neuroscience, Eclipse Bioinnovations, VST Bio, Tr1x) and South San Francisco adding The EVERY Company and Kardigan. China contributes rounds from Shenzhen, Beijing, Changzhou, and Dongli, while Cambridge, UK appears three times — Artios Pharma, PACT, and MISSION Therapeutics — within roughly six weeks. Stage diversity runs from $400K Seed rounds (Gelmedix, MyoGene Bio) to late-stage Series D, with 18 companies classified as Venture - Series Unknown.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this set?
Kailera Therapeutics (Waltham, MA) leads at $600M Series B, followed by Tubulis (Munich) at $358M Series C and Kardigan (South San Francisco) at $254M Series B. Hemab (Copenhagen) raised $157M Series C, while Artios Pharma (Cambridge, UK) and Aspen Neuroscience (San Diego) each closed $115M rounds at Series D and Series C respectively.
Which cities account for the most biotech funding activity in this data?
California dominates, with San Diego hosting four companies (Aspen Neuroscience, Eclipse Bioinnovations, VST Bio, Tr1x), South San Francisco adding The EVERY Company and Kardigan, and the Boston corridor contributing Solarea Bio, Bambusa Therapeutics, and Kailera Therapeutics. Cambridge, UK appears three times (Artios Pharma, PACT, MISSION Therapeutics), and China adds rounds from Shenzhen, Beijing, Changzhou, and Dongli.
How are round stages distributed across these 50 companies?
Venture - Series Unknown is the most common label, covering 18 companies, followed by Series A (10 companies) and Seed (9). Series B accounts for 6 rounds, Series C for 4, and Series D for 3.
What share of these rounds have undisclosed amounts?
Nine of the 50 rounds list undisclosed amounts: JGene Biotechnology, U-Sweet Biotechnology, Zhonghe Gene, Bambusa Therapeutics, Proteine Resources, Taihao Biotechnology, Renewal Bio, Precision Neuroscience, and BayOmics. Most are China-based companies or early-stage rounds where public disclosure is uncommon.
Which round stage accounts for the most capital raised in aggregate?
Series B rounds collectively represent the largest disclosed total, driven by Kailera Therapeutics ($600M), Kardigan ($254M), Peptilogics ($78M), Gate Bioscience ($65M), BridGene Biosciences ($28M), and Enze Kangtai ($14M) — over $1B combined. Series C follows, anchored by Tubulis at $358M and Hemab at $157M.
How active is European biotech funding in this window?
European rounds appear across at least ten companies spanning six countries. The largest are Tubulis (Munich, $358M Series C), Hemab (Copenhagen, $157M Series C), and Artios Pharma (Cambridge, UK, $115M Series D), with smaller closes from PACT and MISSION Therapeutics (both Cambridge, UK), Cellcolabs (Solna, Sweden), EVerZom (Paris), Chromologics (Søborg, Denmark), arcoris bio (Schlieren, Switzerland), and Ona Therapeutics (Barcelona).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.